Receiver operating characteristic curve for anti-NIE antibodies for <i>S. stercoralis.</i> by Jannet A. Tobon Ramos (20855642)

“…Twelve months following MDA, the seroprevalence decreased in the IDA arm to 88 of 212 (41.5%) compared to 100 of 185 (54%) in the DA arm (<i>p</i> = 0.012, chi-square) (<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0012851#pntd.0012851.t004" target="_blank">Table 4A</a>). …”

Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

Figure S2 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes by Pauline J. van der Watt (15068109)

Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance by Niklas Klümper (15048887)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance by Niklas Klümper (15048887)

IGF1R was phosphorylated on hypoxic GRPs, and knockdown of IGF1 decreased the population of CD133- and Oct4-positive hypoxic GRPs. by Akiko Murakami (515972)

DURING THE CORONAVIRUS (COVID-19) PANDEMIC, DOES WEARING A MASK IMPROVE OR WORSEN PHYSICAL PERFORMANCE? by Paulo Roberto Santos-Silva (2735518)

“…Secretory immunoglobulin A (IgA) is an antibody protein used by the immune system to neutralize pathogens, including viruses, and decreases with intense exercise. …”

The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia by Daniel Landau (440830)

“…Rats were sacrificed 4 weeks after CKD induction and 5 minutes after a single bolus of IV recombinant human EPO. …”

Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model by Lara J. Wolfson (7224623)

“…We ran the model including and excluding HZ-related costs and impact of exogenous boosting.</p><p>Results</p><p>Five years post-introduction of UVV (1D), the projected varicella incidence rate decreases from 1,674 cases pre-vaccine to 80 cases/100,000 person-years. …”

Targeted genetic screening in mice through haploid embryonic stem cells identifies critical genes in bone development by Meizhu Bai (6905372)

“…This yielded 4 genes: <i>Zic1</i> and <i>Clec11a</i>, which are required for bone development, and <i>Rln1</i> and <i>Irx5</i>, which had not been previously considered. …”

Unit^a and total costs^b ($US) of HIV testing services (HTS) at correctional facilities in 2017. by Rachel Mukora (10949459)

Study-related adverse events. by Benjamin R. Lewis (22279166)

“…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

Study flow chart. by Benjamin R. Lewis (22279166)

“…In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”